MedTrace Logo

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

NCT00529191 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-03-13

Study results available
· View outcomes & findings →

Summary

The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).

Conditions

Interventions

DRUG

Atorvastatin

Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months

OTHER

Placebo

One out of three subjects will receive a placebo.

Sponsors & Collaborators

Principal Investigators

  • Steven M Willi, M.D · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-07-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00529191 on ClinicalTrials.gov